Healing Novartis

As agribiz sours, it shifts to health care

It's a mild mid-October day in Basel, and Daniel Vasella, the 46-year-old CEO of Swiss pharmaceuticals giant Novartis, is just back from a whirlwind tour of Asia. One of the highlights, he confides over lunch, was discussing the pros and cons of genetically modified food with the King of Thailand.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.